Last updated on July 2018

Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)


Brief description of study

Primary Objective:

  • To demonstrate that sotagliflozin reduces cardiovascular (CV) mortality and morbidity (composite of CV death or hospitalization for heart failure [HHF]) compared to placebo in hemodynamically stable patients with type 2 diabetes (T2D) and heart failure (HF) with left ventricular ejection fraction (LVEF) <50%, after admission for worsening heart failure (WHF).
  • To demonstrate that sotagliflozin reduces cardiovascular (CV) mortality and morbidity (composite of CV death or hospitalization for heart failure [HHF]) compared to placebo in hemodynamically stable patients with T2D and HF irrespective of LVEF after admission for WHF.

Secondary Objectives:

  • To demonstrate that, when compared to placebo in the toal patient population, sotagliflozin reduces the total number (i.e., including recurrent events) of the following clinical events:
  • Cardiovascular death, HHF or urgent HF visit.
  • To demonstrate that, when compared to placebo, sotagliflozin reduces:
  • The composite of positively adjudicated sustained 50% decrease in eGFR, chronic dialysis, renal transplant or positively adjudicated sustained eGFR <15 mL/min/1.73 m2 in the total patient population.
  • Cardiovascular death in patients with LVEF < 50%.
  • Cardiovascular death in the total patient population.
  • All-cause mortality in patients with LVEF < 50%.
  • All cause mortality in the total patient population.
  • To demonstrate the safety and tolerability of sotagliflozin in the total population in this study.

Detailed Study Description

The estimated study duration for a given patient will be approximately 3 to 32 months.

Clinical Study Identifier: NCT03521934

Contact Investigators or Research Sites near you

Start Over

Trial Transparency email recommended (Toll ...

Investigational Site Number 8400006
Sarasota, FL United States
  Connect »

Trial Transparency email recommended (Toll ...

Investigational Site Number 1240004
Peterborough, Canada
  Connect »

Trial Transparency email recommended (Toll ...

Investigational Site Number 1240007
Scarborough, Canada
  Connect »

Trial Transparency email recommended (Toll ...

Investigational Site Number 7520001
Stockholm, Sweden
  Connect »

Trial Transparency email recommended (Toll ...

Investigational Site Number 8400022
Jacksonville, FL United States
  Connect »

Trial Transparency email recommended (Toll ...

Investigational Site Number 8400004
Wellington, FL United States
  Connect »